Effects Of Propofol Injection On Ovarian Cancer Cell Malignancy In Vitro

Introduction:The rapidly growing global disease burden of cancer has aroused attention worldwide.Surgery is the first-line therapy for most solid tumors.However,even after curative primary resection,metastasis and recurrence of tumor account for a large proportion of long-term mortality.Perioperative anesthetic managements regarding the interaction between the host immune defense and the metastatic potential of the primary tumor has become an increasingly popular research topic within the realm of perioperative medicine.Whether anesthesia plays a crucial role in the recurrence of cancer is still controversial.Due to the insufficiency of high-quality randomized clinical trials,there lacks evidence to support any change in clinical practice.Retrospective clinical studies suggest that propofol-based total intravenous anesthesia(propofol-TIVA)could be a better approach than volatile anesthesia to reduce cancer recurrence risk and improve overall survival(OS).In vitro cell experiments have consistently shown the potential of propofol to inhibit the malignancy of numerous types of cancer cells,distinguishing it from volatile anesthetics and other intravenous anesthetics.Propofol suppresses the proliferation,migration,invasion,and angiogenesis of cancer cells by regulating different cell signal pathways,reducing chemoresistance.We aim to investigate the effect of propofol injection(the formulation for clinical use)on ovarian cancer cell malignancy in vitro.Methods:① Cell culture and drug treatment:Human ovarian cancer cell lines SK-OV-3 and ES-2 were obtained from China Infrastructure of Cell Line Resource and cultured according to their instructions.They were exposed to 1,5,10,and 20 μg/ml propofol or cell medium(normal control,NC)for 6 hours or 24 hours prior to the experiment.②Cell proliferation assay(CCK-8 assay):Absorbance at 450 nm was detected by a Microplate Reader.③ Cell migration assay:Two chamber Transwell assay and scratch assay.Results:① Effect of propofol injection on ovarian cancer proliferation:Propofol at 5μg/ml significantly increases SK-OV-3 cell proliferation 6 h post exposure(p<0.05).Propofol at 20 μg/ml significantly increases SK-OV-3 cell proliferation 6 h post exposure(p<0.01).Propofol at μg/ml significantly increases ES-2 cell proliferation 24 h post exposure(p<0.001).②Effect of propofol injection on ovarian cancer migration:Transwell assay and scratch assay showed no statistically significant difference.③Effect of intralipid on ovarian cancer proliferation:Intralipid corresponded to the concentration of intralipid in the 5 μg/ml dose of propofol significantly increases SK-O V-3 cell proliferation 24 h post exposure(p<0.01).Intralipid corresponded to the concentration of intralipid in the 10 μg/ml and 20 μg/ml doses of propofol significantly increases SK-OV-3 cell proliferation both 6 h and 24 h post exposure(p<0.001).Conclusions:① Propofol injection in intralipid(the formulation for clinical use)at clinically relevant concentrations significantly promotes ovarian cancer cell proliferation in vitro.② Intralipid corresponded to the concentration of intralipid in the clinically relevant doses of propofol significantly promotes ovarian cancer cell proliferation in vitro.③ Propofol injection in intralipid(the formulation for clinical use)at clinically relevant concentrations has no effect on ovarian cancer cell migration in vitro.